| Closed |
S1712 |
Rando PhII Ruxolitinib + BCR-ABL TKIs in CML w/Molecular Disease |
7/20/2018 |
|
96% |
|
|
| Open |
S1703 |
Disease Monitoring Study |
7/16/2018 |
|
46% |
|
|
| Closed |
S1702 |
Ph II AL amyloidosis isatuximab |
3/8/2018 |
9/30/2019 |
100% |
|
|
| Closed |
S1400K |
Lung-MAP S1400K: c-MET Positive |
2/5/2018 |
12/21/2018 |
64% |
|
|
| Closed |
S1612 |
Older AML |
12/22/2017 |
|
5% |
|
|
| Closed |
S1619 |
Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab |
11/3/2017 |
5/1/2020 |
100% |
|
|
| Closed |
S1613 |
RPh II Pertuzumab+Trastuzumab vs CETIRI mCRC w/HER2 amp |
10/9/2017 |
12/31/2021 |
42% |
|
|
| Closed |
S1400F |
Lung-MAP S1400F: Non-Match-MEDI4736 and Tremelimumab |
10/2/2017 |
3/24/2020 |
51% |
|
|
| Closed |
S1607 |
T-VEC + Pembro in Adv Melanoma follow prog on PD-1 Inhibitor |
10/2/2017 |
11/1/2020 |
67% |
|
|
| Open |
S1501 |
Carvedilol vs No Trt in Prevention of Cardiac Dysfunction in HER-2+ mBrCa |
9/15/2017 |
|
38% |
|
|
| Open |
S1608 |
Randomized Ph II for Relapsed Refractory FL |
8/10/2017 |
|
81% |
|
|
| Closed |
S1616 |
Ipilimumab + Nivolmab in Adv Melanoma follow prog on PD-1 Inhibitor |
7/17/2017 |
|
100% |
|
|
| Closed |
S1602 |
BCG Strain Differences and BCG vaccination in High-Grade Non-Muscle Invasive Bladder Cancer |
2/7/2017 |
12/15/2020 |
100% |
|
|
| Closed |
S1400G |
Lung-MAP S1400G: HRRD - Talazoparib (BMN 673) |
2/7/2017 |
7/23/2018 |
85% |
|
|
| Closed |
S1605 |
Ph II Atezolizumab Local Bladder |
2/7/2017 |
|
85% |
|
|
| Open |
S1609 |
DART |
1/13/2017 |
|
98% |
|
|
| Closed |
S1512 |
Desmoplastic study |
10/20/2016 |
|
100% |
|
|
| Closed |
S1415CD |
Trial Assessing CSF Prescribing, Effectiveness and Risk (TRACER) |
10/7/2016 |
|
93% |
|
|
| Closed |
S1513 |
RPh II of 2nd Line FOLFIRI w/ or w/o Veliparib (ABT888) in met panc cancer |
9/1/2016 |
|
86% |
|
|
| Closed |
S1507 |
Ph II Tram + doce with kras NSCLC + and PD |
7/18/2016 |
3/15/2018 |
100% |
|
|
